

Press Release

Hope Funds for Cancer Research

Media Contact: Kelly Willette
401-847-3286
media@hope-funds.org

Panel Discussion and Fellows Reception

March 4th, 2010

Translational Cancer Research: Opportunities and Challenges: *Revisiting Private Funding's Role in Advancing Compounds Through Clinical Studies*

Panel

Barry Greene

Barry Greene is President and COO of Alnylam Pharmaceuticals, a biotechnology company developing therapies using an RNA interference platform. Prior to Alnylam, Mr. Greene was general manager of oncology at Millennium Pharmaceuticals, Inc. He has also held senior positions at mediconsult.com, AstraZeneca and Andersen Consulting. Mr. Greene received his BS in industrial engineering from University of Pittsburgh and serves as senior scholar at Duke University, Fuqua School of Business. Barry also serves on the boards of Acorda Therapeutics, Inc. and Regulus Therapeutics, LLC.

Antonio J. Grillo-Lopez, M.D.

Dr. Grillo-Lopez led the clinical development of Rituxan® which was approved in 1997 by the FDA for the treatment of patients with low-grade or follicular non-Hodgkin's lymphoma, and the development of Zevalin, the first radioimmunotherapy approved for the treatment of cancer. Dr. Grillo-Lopez held senior positions at IDEC Pharmaceuticals, DuPont Merck and Parke Davis. Prior to entering industry, he was an Associate Professor of Medicine at the University of Michigan. Dr. Grillo-Lopez trained as a hematologist and oncologist at the University of Puerto Rico School of Medicine, San Juan.

William C. Hahn, M.D., Ph.D.

Dr. Hahn is an associate Professor of Medicine at Harvard Medical School. Dr. Hahn received his MD and PhD from Harvard Medical School in 1994. He then completed clinical training in internal medicine at Massachusetts General Hospital and medical oncology at DFCI. He conducted his postdoctoral studies with Dr. Robert Weinberg at the Whitehead Institute and joined the faculty at Dana Farber Cancer Institute and Harvard Medical School in 2001.

Amy Dockser Marcus

Ms. Dockser Marcus is a Boston-based staff reporter for the Wall Street Journal, and has written extensively about patients with rare diseases, particularly those who get rare cancers. In 2005, she was awarded the Pulitzer Prize for Beat Reporting for a series of stories that she wrote about the physical, monetary, and emotional costs of living with cancer. She is a graduate of Harvard University.

Boston Athenaeum

10 1/2 Beacon Street (near the State House)

Boston

Cocktail or Business Attire

Reception at 5:30 Panel at 6:00 Poster Session with Hope Funds Fellows at 7:15

Benefiting

Innovative research directed at the most difficult-to-treat and most under funded cancers

Committee

Mr. and Mrs. Charles V. Baltic III
Miss Ashley Bickford
Mr. Zachariah Bowyer & Ms. Jennifer Sabo
Ms. Kathy Burdon
Ms. Leah Rush Cann

Ms. Kelly Dolan
Mr. and Mrs. William P. Egan
Ms. Melissa Eisenstat
Dr. Wolfram Goessling
Miss Lily Hayes
Mr. Paul Maxwell
Mr. John Naughton
Mr. and Mrs. Jonathan Pardee
Mr. John E. Parks and Mr. Dominick G. Oddo
Mr. Christopher Pinault
Dr. John Quackenbush
Miss Kelly Willette

For information about attending this event visit: www.hope-funds.org/events/

✉ **SafeUnsubscribe®**

This email was sent to naughjo@verizon.net by media@hope-funds.org.
[Update Profile/Email Address](#) | Instant removal with [SafeUnsubscribe™](#) | [Privacy Policy](#).

Email Marketing by



Hope Funds for Cancer Research | 226 Bellevue Avenue | Newport | RI | 02840